BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20371768)

  • 1. A trojan horse for Parkinson's disease.
    Hu Y; Tong Y
    Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in LRRK2 as a cause of Parkinson's disease.
    Giasson BI; Van Deerlin VM
    Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advance of the study on LRRK2 gene in Parkinson's disease].
    Zhang Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
    West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.
    Bravo-San Pedro JM; Gómez-Sánchez R; Niso-Santano M; Pizarro-Estrella E; González-Polo RA; Fuentes JM
    Biochem Soc Trans; 2012 Oct; 40(5):1129-33. PubMed ID: 22988877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
    Kumari U; Tan EK
    FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
    Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
    PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 for beginners: six key questions.
    Kett LR; Dauer WT
    Cold Spring Harb Perspect Med; 2012 Mar; 2(3):a009407. PubMed ID: 22393539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.